Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS. This is an ASCO Meeting Abstract from the ...
Proceedings of the 64th-67th Annual Meetings for the years 1970-1973 were issued with The American Journal of International Law. However, the 15th-63rd Annual Meetings were issued as part of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results